Clinical Insights

UCB Study Highlights the Burden of Ocular Myasthenia Gravis

UCB Study Highlights the Burden of Ocular Myasthenia Gravis

Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG) and explains how patient perspectives could improve clinical research and care.

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Syndax REVEAL Clinical Trial Banner
C3G and the Pediatric VALIANT Study

C3G and the Pediatric VALIANT Study

Bradley Dixon, MD, pediatric nephrologist, discusses complement 3 glomerulopathy (C3G) and the pediatric VALIANT study. 

Recent Videos

Social Wall

Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati, discusses the findings from the phase 3 ADVANCE OUTCOMES trial of oral ralinepag in patients with pulmonary arterial hypertension (PAH) and their implications for PAH treatment.

View the full Read moreinterview at https://checkrare.com/analysis-finds-ralinepag-reduces-clinical-worsening-across-pah-risk-profiles/

Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD).

View the full interview at Read morehttps://checkrare.com/phinder-analysis-highlights-the-need-for-earlier-pulmonary-hypertension-screening-in-interstitial-lung-disease/

CheckRare is proud to be covering #SNO2026. Stay tuned for our coverage and Expert Insights.

The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease

New research is helping advance the understanding and treatment of rare kidney diseases.

The VALIANT study evaluated pegcetacoplan, a targeted complement therapy, in patients with C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Explore the study Read moreand hear more about the importance of advancing treatment options for patients, including children.

Read the full story: https://checkrare.com/c3g-and-the-pediatric-valiant-study/

New research is helping advance the understanding and treatment of rare kidney diseases.

The VALIANT study evaluated pegcetacoplan, a targeted complement therapy, in patients with C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Explore the

The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease

Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG) and explains how patient perspectives could improve clinical research and Read morecare.

View the full interview at https://checkrare.com/ucb-study-highlights-the-burden-of-ocular-myasthenia-gravis/

What should you know about myasthenia gravis?

From understanding the underlying disease mechanisms to exploring FDA-approved treatment options and ongoing clinical research, staying informed is essential for the rare disease community.

The Myasthenia Gravis Disease Learning CenterRead more brings together educational information and resources to help patients, caregivers, and healthcare professionals better understand this complex condition.

Explore the learning center: https://checkrare.com/myasthenia-gravis/

#MyastheniaGravis #RareDiseaseEducation #HealthcareProfessionals #ClinicalResearch #PatientEducation

What should you know about myasthenia gravis?

From understanding the underlying disease mechanisms to exploring FDA-approved treatment options and ongoing clinical research, staying informed is essential for the rare disease community.

The Myasthenia Gravis Disease Learning